Abstract

Background – A study was undertaken to clarify whether the Pi SZ phenotype of the protease inhibitor system predisposes to chronic obstructive pulmonary disease (COPD).

Methods – The prevalence of PI Z and PI SZ deficient phenotypes was investigated in a population of 702 patients with COPD followed up at the Chest Unit of a tertiary hospital and in 15,400 newborn infants from the same geographical area. Individuals with deficiency were detected by screening of dried blood spots on filter paper using a comparative electroimmunodiffusion technique for \( \alpha_1 \)-antitrypsin and transferrin. The serum phenotype was confirmed by means of isoelectrofocusing on polyacrylamide gel.

Results – Of the 702 blood samples from patients with COPD, six PI Z subjects (0.85%) and one PI SZ (0.14%) were detected. Of the 15,400 samples from neonates, the number of PI Z subjects was eight (0.052%) and that of PI SZ was 24 (0.156%). The difference between the two groups was significant for PI Z but not for PI SZ.

Conclusions – The data do not indicate an increased risk for development of COPD associated with the PI SZ phenotype but confirm the predisposition of PI Z individuals for the development of COPD.

Keywords: \( \alpha_1 \)-antitrypsin, chronic obstructive pulmonary disease, neonates, screening.

PI SZ phenotype in chronic obstructive pulmonary disease

L. Alvarez-Granda, M J Cabero-Perez, A Bustamante-Ruiz, D Gonzalez-Lamuño, M Delgado-Rodriguez, M Garcia-Fuentes
CLINICAL STUDY
Case histories were taken from all PI Z and PI SZ individuals who underwent physical examination and analysis of basic haematological and biochemical parameters including hepatic enzymes. PI Z and PI SZ individuals from the population with COPD also underwent chest radiography, computed axial tomographic (CT) scanning, spirometric and pulmonary function tests.

DATA ANALYSIS
The comparison of prevalences was carried out using the Fisher exact test.

Results
There was a predominance of men (79.8%), of smokers (80.5%), and of those aged 40–60 years (57.4%) in the study population. Mean (SD) FEV1 was 1.14 (0.32) l (56 (17)% predicted). FEV1/FVC was 54 (14%).

Of the 702 patients with COPD subjected to screening, 17 (2.4%) were found to have an α1-antitrypsin/transferin ratio of less than 0.65. Phenotype determination showed that six of these were PI Z and one was PI SZ; the rest consisted of five PI MZ, three PI MS, and two PI MM. In the neonate population, 58 (3.8/1000) suspect samples were detected of which eight were PI Z and 24 PI SZ; the remaining suspect samples consisted of one PI FS, three PI SS, five PI MZ, five PI MS, six PI MM, and six infants whose phenotype we were unable to determine. The number of PI Z individuals found in the group of patients with COPD was significantly higher (p <0.001) than that found in the neonates. The difference was not significant for PI SZ (p = 0.975).

The six COPD patients with PI Z presented with emphysema (table 1). Four subjects were aged ≤ 40. All presented with radiological and CT findings compatible with emphysema. The PI SZ individual detected was a 60 year old man with clinical and spirometric criteria of COPD five years previously. After his inclusion in the study population he was diagnosed as having extrinsic allergic alveolitis after exposure to avian antigens.

With respect to the neonate population, four of the eight PI Z individuals detected presented with hepatomegaly; one child developed cirrhosis and portal hypertension, while the other three presented at one year with persistent hepatomegaly and raised hepatocellular enzymes. The remaining four PI Z individuals were asymptomatic with no biochemical changes. The 24 PI SZ neonates were also asymptomatic, and only one presented with slightly raised hepatocellular enzymes.

Discussion
Although the association between the PI Z phenotype and the development of pulmonary emphysema is well known, it is at present impossible to predict the natural history of a PI Z individual. The number of PI Z individuals with emphysema is well below the total number of these individuals in the population10 and, in most screening studies carried out on the general population, the PI Z individuals detected present with low levels of respiratory disease.11 This lack of knowledge is more marked when we consider PI SZ individuals. It is unclear whether this phenotype involves a risk of developing pulmonary emphysema. Further understanding on this matter is important as the number of PI SZ individuals in the population is 2–3 times greater than that of the PI Z phenotype.

In the controversy about the pulmonary involvement of this phenotype, an initial study described the association of PI SZ with pulmonary emphysema3 which resulted in PI SZ being considered a risk phenotype. However, the number of PI SZ individuals recorded with emphysema is clearly lower than the number of PI Z individuals despite being a more frequent phenotype, and this suggests that the SZ phenotype does not involve any special risk for the development of respiratory disease.6 The number of studies on the prevalence of PI Z and PI SZ individuals in COPD populations is small. Only two studies have analysed populations of over 500. Lieberman7 found a prevalence of PI Z of 1.9% in 965 patients with COPD and reported no difference between these patients and normal individuals with regard to the number with the PI SZ phenotype. On the other hand, Bartman5 found five PI Z and 18 PI SZ individuals in 526 patients with COPD compared with two PI Z and one PI
SZ individuals in the control population. In our study we have found only one PI SZ individual among the patients with COPD, the same frequency as in our control group. However, because of the low prevalence of PI SZ in the population, larger studies may be necessary to exclude a small increase in COPD with PI SZ phenotype.

It was unknown before the beginning of our study whether PI SZ caused ill health so we chose neonates as a control population. In control groups of healthy adults the prevalence of PI Z and PI SZ may be underestimated because these individuals may develop initial symptoms in the second decade of life and are thus not adequately represented in control populations of adult groups.

Our study shows no involvement of the SZ phenotype in the risk for COPD. The frequency of COPD in PI Z individuals was far higher than that found in the neonate population (p <0.001), thus confirming the results of other studies with small populations of patients with COPD.

4 Larson C, Dirksen H, Sundstrem G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (PiZ) reduced levels of alpha-1-antitrypsin. Scand J Respir Dis 1976;57:345–51.
PI SZ phenotype in chronic obstructive pulmonary disease.

L Alvarez-Granda, M J Cabero-Perez, A Bustamante-Ruiz, D Gonzalez-Lamuño, M Delgado-Rodriguez and M Garcia-Fuentes

Thorax 1997 52: 659-661
doi: 10.1136/thx.52.7.659

Updated information and services can be found at:
http://thorax.bmj.com/content/52/7/659

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (968)
- Screening (epidemiology) (366)
- Screening (public health) (366)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/